Foundayo vs Zepbound: What Nine Percentage Points of Body Weight Cost

Last reviewed 19 August 2026 · Educational, not medical advice · No sponsorships, no affiliate links

Clearing up the dose confusion first

If you have read the ATTAIN-1 results you will have seen orforglipron dosed at 6, 12, and 36 mg. The approved tablet tops out at 17.2 mg. This looks like the FDA cut the dose in half. It did not.

The trial used capsules; the marketed product is a tablet with different bioavailability. Lilly maps them directly: capsule doses of 1, 3, 6, 12, 24, and 36 mg correspond to tablet strengths of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. So the 17.2 mg tablet is the 36 mg trial dose, and the 11.2% weight loss figure is what the top approved dose delivered. Anyone telling you the approved dose is weaker than the studied dose has misread the label.

What nine percentage points of body weight actually costs you

For a 100 kg starting weight, the difference between these two drugs at 72 weeks is roughly 9 kg. That is the price of not injecting.

The mechanism explains it. Zepbound is tirzepatide, which activates both the GIP and GLP-1 receptors. Foundayo is orforglipron, which activates GLP-1 only. Adding GIP is the single biggest source of extra weight loss in this drug class, and no oral agent has it yet. Foundayo is not a weaker version of Zepbound; it is a different pharmacology that happens to be swallowable.

Put in context, Foundayo lands roughly where injectable semaglutide sits, not where tirzepatide sits. Semaglutide reached 13.7% in SURMOUNT-5 and the Wegovy pill reached 13.6% in OASIS-4 - both above Foundayo, on cross-trial numbers that should be read loosely. The oral class as a whole currently clusters in the low teens.

The pill is less well tolerated at the top dose, not more

The assumption that swallowing a tablet is gentler than injecting does not survive the data. In ATTAIN-1, adverse events led 5.3% to 10.3% of orforglipron patients to discontinue, depending on dose, against 2.7% on placebo. In SURMOUNT-5, gastrointestinal events drove 2.7% of tirzepatide patients off the drug.

Different trials, different comparators, so treat this as a rough signal rather than a measurement. But the signal points the wrong way for the pill, and the reason is plausible: a daily oral GLP-1 agonist produces daily peak concentrations in the gut, where most of the side effects come from. Weekly injection produces a flatter curve.

Foundayo also has a drug-interaction problem that peptides simply do not have. It is metabolised by CYP3A4, so the maximum dose drops to 9 mg - roughly half - if you are taking a strong CYP3A4 inhibitor. Tirzepatide, being a peptide, has no meaningful CYP interactions. If you are on a protease inhibitor, certain antifungals, or clarithromycin, that constraint is real and it caps your ceiling below the dose the efficacy data came from.

What the pill genuinely wins on

Having spent three sections on the case against, the case for is real and it is not only about squeamishness.

• No food or water restrictions. This is the underrated one. The Wegovy pill and Rybelsus both require an empty stomach and a 30-minute wait before food, drink, or any other oral medication. Foundayo has none of that - take it whenever. Among oral GLP-1 drugs, this is its clearest advantage, and it is why the more instructive comparison for many people is Foundayo against tirzepatide as molecules rather than against the pill from Novo Nordisk.
• No refrigeration. Room-temperature storage removes the cold chain, which matters for travel, for people without reliable refrigeration, and eventually for supply in markets that never got the injectables.
• No needles, no injection sites, no sharps disposal. For a meaningful minority this is the difference between starting treatment and not starting it.
• Manufacturing scale. A small molecule made in standard pharmaceutical plants can be produced at volumes peptide synthesis struggles to match. That is a supply argument, not a clinical one, but the 2023-2024 shortages made it a patient-facing issue.

The adherence argument, stated honestly

There is a serious case that the efficacy gap understates Foundayo in practice, and it deserves to be made properly rather than dismissed.

Roughly half of people who start a GLP-1 drug stop within a year. A propensity-matched study of over 18,000 US patients found 55.9% of tirzepatide patients and 52.5% of semaglutide patients had discontinued by twelve months; a Danish national cohort of 77,310 adults found 52% stopped inside a year. A trial result of 20.2% is worth nothing to someone who quits in month four. If a pill with no needles, no cold chain, and no timing rules keeps materially more people on treatment, some of the nine-point gap closes on its own.

The honest caveat: nobody has measured this. Foundayo launched in April 2026. There is no persistence data, no head-to-head against any injectable, and no real-world cohort. The adherence argument is currently a hypothesis with good priors, not a finding. Anyone presenting it as established is guessing.

Track the doses, not just the scale

Which leaves you somewhere unusual. Because nobody has measured whether the pill actually keeps more people on treatment, the only adherence evidence that exists for your case is the evidence you generate. That is not a consolation prize - on a decision this finely balanced, it is the deciding data, and it costs nothing but the discipline of writing things down.

That is worth taking literally, because daily and weekly drugs fail in different ways. A weekly injection fails by a missed week, which is obvious and recoverable. A daily tablet fails by drift - four missed days in a month that nobody notices, spread thin enough to feel like nothing while quietly costing you a chunk of your dose. The scale will eventually show it. The log shows it three months earlier.

So track doses taken, not only weight. Zenday App is our top-ranked GLP-1 companion at 4.55/5 and works across both rhythms, holding the dose schedule, food, and side-effect days in one place from first dose through maintenance; an independent 2026 study puts six-month weight loss at 2.4x medication alone. On an 11.2% drug, a multiplier like that is not a rounding error - it is a larger effect than the difference between the two doses at the top of the Foundayo ladder. The full scoring is in ourGLP-1 app ranking.

Cost, worked out

Foundayo’s $149 headline is the price of the 0.8 mg starting tablet, which you take for one month. The ladder runs $149, $199, $299 at 5.5 and 9 mg, and $349 at 14.5 and 17.2 mg, dropping to $299 at those top doses under the Self Pay Journey Program if you refill within 45 days.

Titrating to the top and holding it for the rest of a 72-week course costs about $5,132: $149 + $199 + $299 + $299 + $299, then 13 more fills at $299. Divided by 11.2%, that is $458 per percentage point. The equivalent Zepbound course is $299 + $399 + 16 fills at $449 = $7,882, or $390 per point.

So the pill costs 35% less in absolute terms and 17% more per unit of result. Whether that is a good trade depends entirely on whether you would have stayed on the injection.

What the evidence does not show

• No head-to-head trial. Everything above compares ATTAIN-1 against SURMOUNT-5. Same manufacturer, same duration, different populations and comparators.
• No outcome data for Foundayo. No cardiovascular trial, no sleep apnea data, no liver or kidney data. Zepbound at least holds a sleep apnea indication.
• No persistence or real-world data for Foundayo at all. It is four months old.
• No long-term safety record for the molecule class. Orforglipron is the first non-peptide GLP-1 agonist approved anywhere.

How to choose

• You want the most weight loss available: Zepbound, by a wide margin.
• You have obstructive sleep apnea: Zepbound. Foundayo has no indication beyond obesity.
• Needles are why you have not started: Foundayo. An 11.2% result you take beats a 20.2% result you decline.
• You take a strong CYP3A4 inhibitor: Zepbound, or accept that Foundayo caps at 9 mg.
• You travel constantly or cannot rely on refrigeration: Foundayo removes a real logistical problem.
• You want a pill and the most weight loss a pill can give: compare Foundayo against the Wegovy pill, which reached 13.6% - more, but at the cost of an empty stomach and a 30-minute wait every morning.

Method and sources

Foundayo figures come from ATTAIN-1 as published and the US prescribing information; the 11.2% is the treatment-regimen estimand, not the 12.4% efficacy estimand quoted in the approval press release. Zepbound figures come from SURMOUNT-5. Prices are US manufacturer self-pay rates from LillyDirect, read on 19 August 2026. We take no money from Eli Lilly or any other manufacturer and run no affiliate links. For the wider picture, see semaglutide vs tirzepatide and Wegovy vs Zepbound.